Home Clinical Practice Diabetes Education Clinical Research Physician Profiles What's New? F-A-Q's Map to DGD |
Physician Profiles
Sherwyn L. Schwartz, M.D. |
Fellowship, Endocrinology and Metabolism, St. Luke’s Presbyterian Hospital, Chicago, Illinois, 1975 - 1976
Residency, Internal Medicine, Michael Reese Hospital, Chicago, Illinois, 1973 - 1975
Internship, Internal Medicine, Michael Reese Hospital, Chicago, Illinois, 1972 - 1973
MD, University of Illinois, Chicago, Illinois, 1968 - 1972
Bachelor of Science in Biology with Honors, University of Illinois, Chicago, Illinois, 1964 – 1968
American Board of Endocrinology and Metabolism
American Board of Internal Medicine
National Advisor for Diabetes to Merck- Medco, 1995 to present
LULAC (League of United Latin American Citizens) National Medical Advisor for Diabetes Research, 1989
Director, Diabetes Center of Excellence, Methodist Specialty & Transplant Hospital (formerly San Antonio Community Hospital), San Antonio, Texas, 1983 – present
Director, Diabetes & Glandular Disease Research Associates, San Antonio, Texas, 1983 – present.
Director, Diabetes & Glandular Disease Clinic, San Antonio, Texas, 1979 – present
Clinical Professor – Medicine/General Medicine. The University of Texas Health Science Center at San Antonio. From September 1, 2001 through August 31, 2003.
Reviewer for Diabetes Care. 1995 to present.
Endocrinology Consultant, Brook Army Medical Center, Fort Sam Houston, Texas, 1979 - 1985
Assistant Professor of Endocrinology, University of Texas Health Science Center, San Antonio, Texas, 1979 - 1981
Instructor, St. Luke’s Presbyterian Hospital, Chicago, Illinois, 1976 – 1977
Takeda Pharmaceuticals America, Inc. Actosä Speakers Bureau, current
Bayer Consultants Advisory Board, current
Purdue Pharma Consultant Advisory Board, current
Lilly Device Consultants Advisory Board, current
Pharmacia & Upjohn Advisory Board, current
Merck-Medco Advisory Board, current
Parke-Davis Troglitazone Advisory Board, current
Diabetes Forecast Editorial Advisory Board, current
Quality Outcomes In Diabetes Editorial Advisory Board, current
American College of Physicians, current
American Diabetes Foundation, San Antonio Chapter, Medical Advisory Board, current
Juvenile Diabetes Foundation, San Antonio Chapter, Medical Advisory Board, current
San Antonio Endocrinology Club, current
San Antonio Internists Club, current
American Diabetes Association, current
Texas Diabetes Association, current
The Endocrine Society (former President), current
Bexar County Medical Society, current
CHRISTUS Santa Rosa Medical Center
2827 Babcock Road
San Antonio, Texas 78229
Methodist Specialty and Transplant Hospital
(Formerly San Antonio Community Hospital)
8026 Floyd Curl Drive
San Antonio, Texas 78229
Southwest Texas Methodist Hospital
7700 Floyd Curl Drive
San Antonio, Texas 78229
St. Luke’s Baptist Hospital
7930 Floyd Curl Drive
San Antonio, Texas 78229
Methodist Children’s Hospital
(Formerly Methodist Women’s & Children’s Hospital)
7700 Floyd Curl Drive
San Antonio, Texas 78229
Director, South Texas Clinical Diabetes Symposium, San Antonio, Texas, 1983 - present
Co-Director, 5K Diabetes Run - Humanathon, 1983 - 1987
Member, Glipizide Symposium, Roerig- Pfizer, 1983 - 1986
Advisory Committee, Upjohn Company, 1984
Humulin Advisory Committee, Eli Lilly & Company, 1984
Principal Investigator on over 590 research protocols, 1981 – present
Endocrinology Society of Mexico, 1990
South Texas Regional Symposium, 1990
“The Immunology of Diabetes “, Woods Hole, MA, October 27 -30, 1987.
Southern Medical Association, 1986
Federal Aviation Administration, 1982 - 1985
Texas Medical Association, 1985
Endocrinology and Diabetes Updates - Abilene, Del Rio, Gonzales, Kerrville, Laredo,
New Braunfels, Pearsall, San Angelo, San Antonio, Seguin, Uvalde, and Victoria, Texas,
1983 - present
Department of Biochemistry, University of Texas, 1982
“Predictive Value of ICA for Insulin-dependent Diabetes and Insulinopenia to I.V. Glucose”: International Research Symposium.
and Fat Mass, and Bone Mineral Density in Hypogonadal Men. Christina Wang, Glenn Cunningham, Adrian Dobs, Ali
Iranmenesh, Alvin M. Matsumoto, Peter J. Snyder, Thomas Weber, Nancy Berman, Laura Hull, and Ronald S.
Swerdloff. The Journal of Clinical Endocrinology & Metabolism, Volume 89, Number 5, pp: 2085-208, May 2004**
Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population. Mark J. Brown, MD¹; Shawn
J. Bird, MD¹; Sharon Watling, PharmD²; Hong Kaleta, MS²; Lee Hayes, BSC²; Stephen Eckert, PhD²; Howard L. Font²,
MD, PhD². Diabetes Care, Volume 27, number 5, pp: 1153-1158, May 2004.**
Diabetes. Satish K. Garg, MD¹, Sherwyn L. Schwartz, MD², Steven V. Edelman, MD³. Diabetes Care, Volume 27,
Number 3, March 2004.
Preference and Resource Utilization in Elderly Patients: Innolet ® Versus Vial/Syringe. John Shelmet a*, Sherwyn L.
Schwartzb, John Capplemanc, Gregory Petersond, Soren Skovlunde, Lene Lytzene, Lars Nicklassonf, John Liangf,
William Lyness, Innolet ® Study Group. 1. Available Online via ScienceDirect. November 13, 2003. A PDF. Diabetes
Research And Clinical Practice www.elsevier.com/locate/diabres
Osteoporosis. Anthony B. Hodsman, David A. Hanley, Mark P. Ettinger, Michael A. Bolognese, John Fox, Anna J.
Metcalfe, and Robert Lindsay. Acknowledgements: Sherwyn L. Schwartz, San Antonio, TX. The Journal of Clinical
Endocrinology & Metabolism, (Vol. 88): 5212-5220. November 2003
Type 1 Diabetes. A dose-timing study. Christian Weyer; MD, Alan Gottlieb; PA, Dennis D. Kim, MD; Karen Lutz, PhD,
Sherwyn Schwartz; MD,² Maria Gutierrez, MD; Yan Wang, PHD; James A. Ruggles, PhD; Orville G. Kolterman, MD;
David G. Maggs, MD. Diabetes Care, Volume 26, Number 11, November 2003, pp: 3074-3079.
patients. Mathew C. Riddle, MD; Julio Rosenstock, MD; John Gerich, MD; On behalf of the Insulin Glargine 4002 Study
Investigators*. Diabetes Care, Volume 26, Number 11, November 2003, pp: 3080-3086.
Insulin 70/30 Mix Plus Metformin Versus Triple Oral Therapy in the Treatment of Type 2 Diabetes After Failure of Two Oral Drugs. Sherwyn Schwartz, M.D.; Richard Sievers, DO; Poul Strange, M.D, Ph.D.; William H. Lyness, Ph.D.; Priscilla Hollander, M.D.; For The *INS-2061 Study Team. Diabetes Care, Volume 26, Number 8, August 2003, pp: 2238-2243.
Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR* Trial Peter H. Jones, MD; Michael H. Davidson, MD; Evan A Stein, MD, PhD; Harold E. Bays, MD; James M. McKenney, PharmD; Elinor Miller, MD; Valerie A. Cain, MS, and James W. Blasetto, MD, MPH, for the STELLAR Study Group*. © 2003 by Excerpta Medica, Inc. All rights reserved. The American Journal of Cardiology Vol. 92 July 15, 2003, pp: 152-160.
"AA2500 Testosterone Gel Normalizes Androgen Levels in Aging Males With Improvements in Body Composition and Sexual Function". C. Steidel, S. Schwartz, K. Jacoby, T. Sebree, T. Smith, R. Bachand and THE NORTH AMERICAN AA2500 T Gel STUDY GROUP. The Journal of Clinical Endocrinology & Metabolism 88 (6) June 2003, pp:2673-2681.
"Nateglinide Well-Tolerated in Elderly Patients With Diabetes." Sherwyn L. Schwartz, M.D., Boris Draznin, M.D., Endocrine Today. Clinical News on Diabetes and Endocrine Disorders. (Volume pending). May 2003.
"Effects of an anti-CD5 Immunoconjugate (CD5-plus) in recent onset Type 1 Diabetes Mellitus: A Preliminary Investigation: The CD5 Diabetes Project Team." Skler JS, Lorenz TJ, Schwartz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Saria EA, Byers V. Journal Diabetes Complications. Diabetes, Volume 52, May 2003, pp: 7.224-232.
"Recombinant Variant Of Ciliary Neurotrophic Factor For Weight Loss In Obese Adults. A randomized, Dose-Ranging Study." Mark P. Ettinger, M.D.; Thomas W. Littlejohn, M.D.; Sherwyn L. Schwartz, M.D.; Stuart R. Weiss, M.D.; Harris H. McIlwain, M.D.; Steven B. Heymsfield, M.D.; George A. Bray, M.D.; William G. Roberts, M.D.; Eugene R. Heyman, Ph.D.; Nancy Stambler, M.S.; Stanley Heshka, Ph.D.; Catherine Vicary, B.S.; Hans-Peter Guler, M.D. JAMA, April 9, 2003 - Volume 289, No. 14, pp3: 1826-1832.
"A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes." Martin St. John Sutton, FRCP; Mark Rendell, M.D.; Paresh Dandona, M.D.; Jo F. Dole, Ph.D.; Karen Murphy, MT (ASCP); Rita Patwardham, Ph.D.; Jai Patel, M.D.; Martin Freed, M.D.; For The Rosiglitazone Clinical Trials Study Group** Diabetes Care, Volume 25, Number 11. November 2002, pp: 2058-2062.
“Use of an Automated Device for Alternative Site Blood Glucose Monitoring.” S. Edwin Fineberg, M.D.; Richard M. Bergenstal, M.D.; Robert M. Bernstein, M.D.; Lori M. Laffel, M.D.; Sherwyn L. Schwartz, M.D. Diabetes Care 24:1217-1220, 2001
“Importance of Early Insulin Secretion”. Comparison of nateglinide and Glyburide in Previously Diet-Treated Patients With Type 2 Diabetes." Priscilla A. Hollander, M.D., Ph.D., Sherwyn L. Schwartz, M.D., Marjorie R. Gatlin, M.D. Stephen J. Haas, B.S., Hongjie Zheng, B.S., James S. Foley, Ph.D., Beth E. Dunning, Ph.D.
Diabetes Care 24:983-988, 2001.
“Sugar-Free Zinc Gluconate Glycine Lozenges (Cold Eeze®) Do Not Adversely Affect Glucose Control in Patients with Type 1 or Type 2 Diabetes Mellitus." Sherwyn L. Schwartz, M.D.; Jerome S. Fischer, M.D.; Mark S. Kipnes, M.D. American Journal Of Therapeutics, 1075-2765 © 2001 Lippincott Willisms & Wilkins pp. 006-0611
“Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovarian Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial." Ricardo Azziz, David Ehrmann, Richard S. Legro, Randall W. Whitcomb, Rochelle Hanley, Anita Gmerek Fereshetian, Mary O’Keefe, and Mahmoud N. Ghazzi FOR THE PCOS/TROGLITAZONE STUDY GROUP*. The Journal of Clinical Endocrinology & Metabolism. Volume 86, No. 4, pp. 1626-1632. Copyright© 2001 By The Endocrine Society.
“Physiological Influences on Off-finger Glucose Testing." Geoff McGarraugh, David Price, M.D., Sherwyn Schwartz, M.D., Richard Weinstein, M.D. Diabetes Technology and Therapeutics. Copyright© 2001.
“A Global Study of Vitamin D Status and Parathyroid Function in Postmenopausal Women with Osteoporosis”: Baseline Data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial." Paul Lips, Tu Duong, Anna Oleksik, Dennis Black, Steven Cummings, David Cox and Thomas Nickelsen, FOR THE MULTIPLE OUTCOMES OF RALOXIFENE EVALUATION STUDY GROUP**. The Journal of Clinical Endocrinology & Metabolism. Volume 86, No. 3. Copyright ã 2001 by The Endocrine Society.
“Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin Glargine (HOE 901) and NPH insulin.” Julio Rosenstock, M.D. Sherwyn L. Schwartz, M.D., Charles M. Clark, Jr., M.D., Glen D. Park, Pharmd., David W. Donley, Ph.D., Mike B. Edwards, R.P.H. Diabetes Care, Volume 24, number 4, April 2001, pp. 631-636.
“Efficacy Of A Motilin Receptor Agonist (ABT-229) For Relief Of Dyspepsia In Type 1 Diabetes Mellitus: A Randomized Double Blind Placebo Controlled Trial." N. J. Talley; M. Verlinden; R. W. McCallum; S. L. Schwartz; D. J. Greenen; R. J. Mack; E. B. Portnoy; R. B. Hogan; C. Schmitt; J. S. Morgan. Gut, An International Journal of Gastroenterology and Hepatology. December 2000.
“Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy. A Randomized Controlled Trial.” Stuart C. Apfel, M.D.; Sherwyn L. Schwartz, M.D.; Bruce T. Adornato, M.D.; Roy Freeman, M.D.; Victor Biton, M.D.; Marc Rendell, M.D.; Aaron Vinik, M.D.; Michael Giuliani, M.D.; J. Clarke Stevens, M.D.; Richard Barbano, M.D., Ph.D.; Peter J. Dyck, M.D.; for the rhNGF Clinical Investigator Group. Journal of the American Medical Association, November 1, 2000, Volume 284, Number 17, pp. 2215-2221.
"Therapy Focused on Lowering Postprandial Glucose, Not Fasting Glucose, May Be Superior for Lowering HbA1c." Edward J. Bastyr, III, M.D., Charles A. Stuart, M.D., Robert G. Brodows, M.D., Sherwyn Schwartz, M.D., Casey J. Graf, Pharmd, Anthony Zafar, MS, Kenneth E. Robertson, Pharmd, For the IOEZ Study Group. Diabetes Care, Volume 23, Number 9, September 2000, pp. 1236-1241.
“Rapaglinide/Troglitazone Combination Therapy. Improved Glycemic Control in Type 2 Diabetes." Philip Raskin, M.D.; Lois Jovanovic, M.D.; Sheldon Berger, M.D.; Sherwyn Schwartz, M.D.; Vincent Woo, M.D.; Robert Ratner, M.D. Diabetes Care, Volume 23, Number 7, July 2000, pp. 979-980.
“Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men*." Christina Wang, Ronald S. Swerdloff, Ali Iranmanesh, Adrian Dobs, Peter J. Snyder, Glenn Cunningham, Alvin M. Matsumoto, Thomas Weber, Nancy Berman, and The Testosterone Gel Study Group: S. Berger, E. Dula, J. Kaufman, G.P. Redmond, S. Scheinman and H. W. Hutman, S. L. Schwartz, C. Steidle, J. Susset, L. L. C.; and R. E. Dudley, S. Faullkner, N. Rohowsky, G. Ringham, W. Singleton, J. Longstreth and K. Zunich. The Journal of Clinical Endocrinology & Metabolism, Volume 85, No. 8, May 12, 2000. Copyright ã 2000 by The Endocrine Society.
“Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus.”, The New England Journal of Medicine. S. Schwartz, P. Raskin, V. Fonseca, J. F. Graveline, Volume 338, Number 13, Copyright 1998, pp. 861-866.
“Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus.” Miroslav Backonja, M.D.; Ahmad Beydoun, M.D.; Keith R. Edwards, M.D.; Sherwyn L. Schwartz, M.D.; Vivian Fonseca, M.D.; Marykay Hes, B.S.; Linda LaMoreaux, M.P.H.; Elizabeth Garofalo, M.D.; for the Gabapentin Diabetic Neuropathy Study Group, The Journal of the American Medical Association: Volume 280, Number 21, Copyright 1998, pp. 1831-1836.
“Metformin: Co-Therapy with Sulfonylureas Improves Control in Non-Insulin-Dependent Diabetes Mellitus.” Sherwyn L. Schwartz, M.D., Diabetes and Glandular Disease Research Center, San Antonio, Texas. Advances in Therapy®, Volume 14, No. 4, July/August 1997, pp. 209-212.
“Comparison of the Effects of Estrogen Alone and Estrogen in Plus Androgen on Biochemical Markers of Bone Formation and Resorption in Postmenopausal Women.” Journal of Clinical Endocrinology and Metabolism: Volume 81, No. 1, Copyright 1996, pp. 37-43. Lawrence G. Raisz, Brinda Wita, Althea Artis, Angela Bowen, Sherwyn L. Schwartz, M.D., Margaret Trachiotis , Kamal Shoukri , and Joanne Smith.
“Effects of Simvastatin Versus Gemfibrozil on Lipids and Glucose Control in Patients with Non-Insulin-Dependent Diabetes Mellitus.” Clinical Therapeutics, Volume 17, No. 2, Copyright 1995, pp. 186-203. Anna E. Sweany, M.D., Deborah R. Shapiro, D.P.H., Ann C. Tate, M.S., Ronald B. Goldberg, M.D., on behalf of the NIDDM Study Group.
“Efficacy and Safety of Pravastatin in the Treatment of Patients with Type I or Type II Diabetes Mellitus and Hypercholesterolemia.” The American Journal of Medicine. October 1995, Volume 99. Philip Raskin, MD, Om P. Ganda, MD, Sherwyn L. Schwartz, MD, David Willard, MD, Julio Rosenstock, MD, Peter A. Lodewick, MD, Bonnie Weiner, MD, Mark E. McGovern, MD, Jean M. Norton, MS, Gabriella G. Cucinotta, BS, Bruce D. Behounek, MD.
“Comparison of the Effects of Estrogen Alone and Estrogen Plus Androgen on Biochemical Markers of Bone Formation and Resorption in Postmenopausal Women.” Raisz, Lawrence G.; Wilita, Brinda; Artis, Althea; Bowen, Angela; Schwartz, Sherwyn; Trachiotis, Margaret; and Smith, JoAnne: The Pharmaceuticals (B. W. , A.A.), The Middleton Foundation ( A.B.), and The Diabetes and Glandular Disease Clinic (S.S.) , 1995.
“Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor.” James W. Nawrocki, Stuart R. Weiss, Michael H. Davidson, Dennis L. Sprecher, Sherwyn L. Schwartz, Paul-J. Lupien, Peter H. Jones, Harry E. Haber, Donald M. Black. Arteriosclerosis, Thrombosis, and Vascular Biology, Volume 15, No. 5, Copyright May 1995, pp. 678-682.
“Age and Family Relationship Accentuate the Risk of Insulin - Dependent Diabetes Mellitus (IDDM) in Relatives of Patients with IDDM.” Alan B. Cantor, Jeffrey P. Krischer, David D. Cuthbertson, Desmond A. Schatz, William J. Riley, John Malone, Sherwyn L. Schwartz, Teresa Quattrin and Noel K. Maclaren. Journal of Clinical Endocrinology and Metabolism, Volume 80, No. 12, Copyright 1995.
"Atorvastatin Study 981-04.” Arteriosclerosis, Thrombosis and Vascular Biology, May 1995; 15: pp. 678 – 682.
“Management of Diabetes Mellitus.“ Schwartz, Sherwyn, M.D. Essential Medical Information, Systems, Inc., Durant, Oklahoma, Third Edition, 1993.
“Insulin and Islet Cell Autoantibodies in the Development of Diabetes in Relatives of Patients with Insulin Dependent Diabetes: A Prospective Study.” Krischer, J.P.; Maclaren, N.K.; Riley, W.J.; Spillar, R.P.; Schwartz, S.; Malone, J.; et al: Diabetes 1991.
“A Prospective Study of the Development of Diabetes in Relatives of Patients with Insulin-Dependent Diabetes.” Riley, W. J.; Maclaren, N.K.; Krischer, J.; Spillar, R.P.; Silverstein, J.H.; Schatz, D.A.; Schwartz, S.L.; Malone, J.; Shah, S.; Vadheim, C.; et al: New England Journal of Medicine, 1990, October 25; 323 (17): pp. 1167 - 72.
“Effects of Short-Term Insulin Therapy Upon Therapeutic Response to Glipizide.” Schwartz, Sherwyn L.; Fischer, Jerome S.; Kipnes, Mark S.; and Boyle, Mary. The American Journal of Medicine, (Supl 3A), September 18, 1987, p. 22-30.
“Guidelines to Diabetes Management for the Primary Care Physician." Chairman of the Editorial Board, Professional Education Committee, Texas Affiliate, Inc., American Diabetes Association , 1985.
“Reduction of LDL Cholesterol by 25% to 60 % in Patients With Primary Hypercholesterolemia by Atorvastatin, A New HMG - CoA Reductase Inhibitor." James W. Nawrocki, Stuart R. Weiss, Michael H. Davidson, Dennis L. Sprecher, Sherwyn L. Schwartz, Paul-J. Lupien, Peter H. Jones, Harry E. Haber, Donald M. Black. Riley, W. J.; Maclaren, N.K.; Spillar, R.P.; Schatz, D.A.; Krischer, J.; Silverstein, J.H.; Schwartz, S.L.; Malone, J.; Rotter, J.L.
“ The Use of Islet Cell Auto-antibodies in Identifying Pre-Diabetes.” Excerpta Medica International Congress Series.
* Sherwyn L. Schwartz; The Diabetes & Glandular Disease Clinic Research Center.
"A Phase 2 Clinical Investigation of Pyridoxamine (Pyridorin™) In Type1 and Type 2 Diabetic Patients With Overt
Diabetic Nephropathy (PYR-205/207). Janet B McGill, Thortstein P. Degenhardt, Julie R Sabo, Raja G Khalifah, Robert
J Schotzinger, and PYR-205/207 Study Group**, St. Louis, MO, Durnham, NC Vol. 53, Suppl.2 A.D.A. Meeting in
Orlando, Florida, June 2004.
"The Combination of Testosterone-Gel 1% (AndroGel) and Sildenafil for Treatment of Erectile Dysfunction: Safety
Assessment in Hypogonadal Non-Responders to Sildenafil Monotherapy". Zurab Behia, MD, Ph.D., Cindy Lane,
BSX, John J. Brennan, Ph.D., Lisa M. Zipfel, MS, and Sherwyn L. Schwartz, MD Abstracts, Endocrine Prac. 2004; 10
(Suppl 1) 5.
Alarms Based on Real-Time Sensor Glucose Values Alert Patients to Hypo- and Hyperglycemia: The Guardian
Continuous Monitoring System. Bruce Bode, MD¹, Kenneth Gross, MD², Nancy Rikalo, MD³, Sherwyn Schwartz, MD,
Timothy Wahl, MD, Casey Page, MD6, Todd Gross, PhD, and John Mastrototaro, PhD. Diabetes Technology &
Therapeutics - Volume 6, Number 2, 2004, pp: 105-113.
Prevalence of Co-Morbid Metabolic Abnormalities in Non-Diabetic Overweight/Obese Adults. Steven Weinstein,
Catherine Vicary, Sherwyn Schwartz, Marshall Block, Barbara Tardiff. Abstract scheduled to be presented at the
AACE, April 2004.
"Glucose Profiles in Patients Implanted with a Real-Time, Long-Term, Glucose Sensor." Steven V. Edelman, Sherwyn Schwartz, Satish K. Garg. San Diego, CA, San Antonio, TX Denver, CO. 63rd Scientific Sessions. Presented during: Late Breaking Clinical Studies. - 06/15/2003.
"Mealtime Amylin Replacement with Pramlintide Markedly Reduced Postprandial Glucose Excursions When Added to Insulin Lispro in Patients with Type 1 or Type 2 diabetes". Christian Weyer, Dennis Kim, Terrie Burrell, Yan Wang, Jonathan Konnstein, Tom Bicsak, Mark Fineman, James Ruggles, Sherwyn Schwartz, Orville Kolterman. San Diego, CA; San Antonio, TX. Diabetes: A Journal of The American Diabetes Association ®, A.D.A. Abstract Book, Volume 52, Supplement 1. June 14 to June 17, 2003.
"Insulin Plus Metformin vs. Triple Oral Therapy Following Failure of a Combination of 2 OAD's: Efficacy and Cost of Therapy." Priscilla Hollander; Sherwyn Schwartz; Richard Sievers; Poul Strange; Bob An; William Lyness; Dallas, TX; San Antonio, TX; Kettering, OH; Princeton Junction, NJ; Princeton, NJ. Diabetes: A Journal of The American Diabetes Association ®, A.D.A. Abstract Book, Volume 52, Supplement 1. June 14 to June 17, 2003.
"Static Magnetic Field Therapy for Symptomatic Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Trial." Michael I. Weintraub, M.D., FACP, Gil I. Wolfe, M.D., Richard A. Barohn, M.D., Steven P. Cole, Ph.D., Mark B. Brombert, M.D., Sherwyn L. Schwartz, M.D., and the Magnetic Research Group. Archives of Physical Medicine and Rehabilitation. Volume 84, No. 5, pp: 736-746. May 2003.
“Response To Testosterone Supplementation With a New Topical Testosterone Gel (Testimä) in Older Men With Diabetes Mellitus." Sherwyn L. Schwartz1*; John P. Rodzvilla2, Allen R. Secrest and Ted M. Smith2. 1Diabetes and Glandular Disease Research Associates, P.A., San Antonio, TX, 78229 and 2Auxilium Pharmaceuticals, Inc., Norristown, PA, 19401. Presented at ENDO 2003 in Philadelphia, PA., June 2003.
“Symptoms of Low Testosterone Are a Strong Predictor of Hypogonadism." Sherwyn L. Schwartz1*; John P. Rodzvilla2, Allen R. Secrest and Ted M. Smith2. 1Diabetes and Glandular Disease Research Associates, P.A., San Antonio, TX, 78229 and 2Auxilium Pharmaceuticals, Inc., Norristown, PA, 19401. April 2003.
"Plasma Glucose and Insulin Response to Isocaloric Amounts of Enteral Formulas in Persons with Type 2 Diabetes Mellitus." S.L. Schwartz, M.D.; J. Fischer, M.D.; M. Kipnes, M.D. and L. Kelly, R.N. Diabetes and Glandular Disease Research Center, San Antonio, TX. Currently used by Norvartis Nutritional, in their brochures and on their Website. January, 2003.
“A New Testosterone Gel Normalizes Androgen Levels in Aging Males with Improvements in Body Composition and Sexual Function.” Christopher P. Steidle, Northeast Indiana Urology Research, Fort Wayne, IN; Sherwyn L. Schwartz, Diabetes & Glandular Disease Research Associates, San Antonio, TX; Karny Jacoby, Integreity Medical Research, Seattle, WA; Gary D. Nevins, Auxilium Pharmaceuticals, Norristown, PAA; Ted M. Smith, Auxilium Pharmaceuticals, Norristown, PAA; Tomeo T. Bachand, Auxilium Pharmaceuticals, Norristown, PAA; Randall J. Mack, Auxilium Pharmaceuticals, Norristown, PAA. Selected for presentation at the American Urological Association - 2003 Annual Meeting.
“AXOKINE® Reduces Weight in Severely Obese Subjects and Keeps Weight Stable for a Prolonged Period of Time after Dosing is Stopped.” Mark P. Ettinger, M.D.; Thomas W. Littlejohn, M.D.; Sherwyn L. Schwartz, M.D.; Stuart R. Weiss, M.D.; Harris H. McIlwain, M.D.; Steven B. Heymsfield, M.D.; George A. Bray, M.D.; William G. Roberts, M.D.; Eugene R. Heyman, Ph.D.; Nancy Stambler, M.S.; Catherine Vicary, B.S.; Hans-Peter Guler, M.D. Submitted to the New England Journal Of Medicine, September 25, 2002.
“Diabetic Peripheral Neuropathy (DPN) Assessed by Neurological Examination (NE) and Composite Scores (CS) Is Improved with LY333531 Treatment.” LITCHY, WILLIAM; DYCK, PETER; TESFAYE SOLOMON; ZHANG, DAVID; BASTYR, EDWARD; THE MBBQ STUDY GROUP**. Norfolk, VA; Manchester, England; Rochester, MN; Indianapolis, IN. Selected for presentation at the American Diabetes Association’s 62nd Scientific Sessions in June 2002.
“Detectable Sural Nerve Action Potential (SNAP) Identifies Patients with Early Diabetic Peripheral Neuropathy (DPN)." BRIL, VERA; VINIK, AARON; LITCHY, WILLIAM; ZHANG, DAVID; BASTYR, EDWARD; THE MBBQ STUDY GROUP*. Toronto, Canada, Norfolk, VA; Rochester, MN, Indianapolis, IN. Selected for presentation at the American Diabetes Association’s 62nd Scientific Sessions in June 2002.
“Neuropathy Total Symptom Score-6 Questionnaire (NTSS-6) Is a Valid Instrument for Assessing the Positive Symptoms of Diabetic Peripheral Neuropathy (DPN)”. BASTYR, EDWARD; ZHANG, David; BRIL, VERA; THE MBBQ STUDY GROUP*. Toronto, Canada; Indianapolis, IN. Selected for presentation at the American Diabetes Association’s 62nd Scientific Sessions in June 2002.
“LY333531 Treatment Improves Diabetic Peripheral Neuropathy (DPN) with Symptoms.” VINIK, AARON; SOLOMON, TESFAYE; ZHANG, DAVID; BASTYR, EDWARD; THE MBBQ STUDY GROUP.* Norfolk, VA; Manchester England; Indianapolis, IN. Selected for presentation at the American Diabetes Association’s 62nd Scientific Sessions in June 2002.
“Weight Loss With AXOKINE® Does Not Appear To Be Followed By Rebound Weight Regain.” Weinstein, S.P., Vicary, C., Ettinger, M.P., Littlejohn, T.W., Schwartz, S.L., Weiss, S.L., McIlwain, H.H., Heymsfield, S.B., Bray, G.A., Roberts, W.G., Acheson, A., Stambler, N., Heyman, E.R., Dark, C.L., Guler, H.-P. Regeneron Pharmaceuticals, Inc. Selected for Oral Presentation at the 2001 NAASO Annual Scientific Meeting in Québec City, Québec Canada. October 8, 2001.
"Early Introduction of Oral Insulin in Patients Failing on Diet and Exercise, A Long-term Efficacy Study in Treatment of Type-2 Diabetes.” Sherwyn Schwartz, M.D., Sherri Shade, R.N., Jayne Eaton, R.N., San Antonio, Texas; Pankaj Modi, M.D., Toronto CAN. June 2001.
“Replacement of Failing Sulfonylurea Drugs with Oral Insulin, A Long-term Efficacy Study in Treatment of Type-2 Diabetes.” Sherwyn Schwartz, M.D*.; Sherri. Shade, R.N. Jayne Eaton, R.N., San Antonio, TX., Pankaj Modi, M.D*.; Toronto, CAN. Selected for Oral Presentation at the American Diabetes Association’s 61st Scientific Sessions. Philadelphia, Pennsylvania. June 22-26, 2001.
“COMMUNITY SCREENING FOR DIABETES: SHOULD DEMOGRAPHICS BE A FACTOR?” Mark S. Kipnes, Sherwyn L. Schwartz, Jerome S. Fischer, William F. Trigoso, Amna A. Salhin, Jacob Vadakekalam, Daina Dreimane, William D. Linn. American Association of Clinical Endocrinologists 10th Annual Meeting & Clinical Congress. May 2-6, 2001. San Antonio, Texas.
“Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes." Harold E. Lebovitz, Jo F. Dole, Rita Patwardhan, Elizabeth B. Rappaport, and Martin I. Freed FOR THE ROSIGLITAZONE CLINICAL TRIALS STUDY GROUP*. The Journal of Clinical Endocrinology & Metabolism. Volume 86, No. 1, p. 280. Feb 2001.
“Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus." William T. Cefalu, M.D.; Jay s. Skyler, M.D.; Ione A. Kourides, M.D.; William H. Landschulz, M.D.; Cecile C. Balagtas, Ph.D.; Shu-Lin Cheng, Ph.D.; and Robert A. Gelfand, M.D. for the Inhaled Insulin Study Group*. Annals of Internal Medicine. Volume 134. No. 3. Feb 6, 2001.
Pharmacological Reproducibility of Inhaled Insulin Dosed Pre-meal in Patients with Type 2 DM. Gelfand RA, Schwartz, SL, Horton M, Law CG, Pun EFF. Diabetologia 43 (Suppl. 1): A202, 2000.
Pharmacokinetics and Pharmacodynamics of Pulmonary Insulin Delivered Via The AERx Diabetes Management System in Type 1 Diabetes. Kipnes M, Otulana B, Okikawa J, Farr S, Jendle J, Thipphawong J, Schwartz S. Diabetologia 43 (Suppl. 1): A202, 2000.
“Multi-center Evaluation of a Meter for Blood Glucose and Ketone Monitoring." George S. Cembrowski, Fred S. Apple, Vincent Ricchiuti, Robert H. Christenson, Francisco R. Velazquez, Mary L. Johnson, Robert M. Bernstein, Sherwyn L. Schwartz, Edmonton, AB, Canada. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A62.
“A Comparison of the Pharmacodynamic Effects of Inhaled Insulin versus Subcutaneous Insulin in Type 1 Diabetic Patients." Mark Kipnes, Babatunde Otulana, Per Clauson, Jerome Fischer, Stephen J Farr, Vibeke Hatorp, Sherwyn Schwartz, Hayward, CA. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A95.
“Bromocriptine (Ergosetâ) Improves Glycemic Control in Type 2 Diabetics on Insulin." Sherwyn L. Schwartz, San Antonio, TX. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A99.
“Efficacy and Safety of HOE 901 (Insulin Glargine) in Subjects with Type 2 DM: A 28-Week Randomized, NPH Insulin-Controlled Trial." Julio Rosenstock, Sherwyn Schwartz, Charles Clark, Mike Edwards, David Donley, Dallas, TX. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A100.
“Combination of Insulin Lispro (LP), Metformin (MF), or Bedtime NPH (NPH) with Sulfonylurea (SU) Following Secondary SU Failure." Robert Browdos, Sherwyn Schwartz, Charles A. Stuart, Anthony Zagar, Casey J. Graf, Edward J. Bastyr, and the IOEZ Study Group, Brentwood, TN. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A104.
“Clinical Trial of a Mail-in Test for Measuring HbA1c With Capillary Blood." Randie R. Little, David Goldstein, Altethea Tennill, Hsiao-Mei Wiedmeyer, Dongua Huang, Sherwyn L. Schwartz, Mary L. Johnson, Columbia, MO. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A193.
“Effects of Troglitazone on HbA1c and ALT Levels in Clinical Practice." Sherwyn L. Schwartz, San Antonio, TX. For presentation at the President’s Poster Session and Reception, American Diabetes Association 59th Scientific Sessions, June 20, 1999, San Diego, CA.
“Pharmacologic Reproducibility of Inhaled Human Insulin Pre-Meal Dosing in Patients with Type 2 Diabetes Mellitus (NIDDM)." Robert A. Gelfand, C. Gordon Law, Sherwyn L. Schwartz, Michael Horton, and Edward F. Pun for the Inhaled Insulin Phase II Study Group.
“Troglitazone Plus Sulfonylurea Combination: Long Term Efficacy in Patients with Type 2 Diabetes." Boris Draznin; Joseph Driscoll; Jennifer Sievers; Tom Venable; Mahmoud Ghazzi; V.A. Medical Center, Denver, Colorado; Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan; Sherwyn L. Schwartz, M.D. for The Troglitazone Study Group - Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan.
“Gabapentin (NeurontinÒ) Monotherapy for the Treatment of Painful Neuropathy: A MultiCenter, Double-Blind, Placebo-Controlled Trial in Patients with Diabetes Mellitus." Keith R. Edwards, Neurological Consultants, PC, Bennington, VT; Marykay Hes, Linda LaMoreaux, Edwina Koto, Elizabeth Garofalo, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan; Sherwyn L. Schwartz, M.D. for US Gabapentin Study Group 210 – Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan.
“Minimal Endometrial Proliferation Over a Two-Year Period in Postmenopausal Women Taking 0.3 mg of Unopposed Esterified Estrogens." Morris Notelovitz; R. Edward Varner; Robert W. Rebar; Roy Fleischmann; Harris H. McIlwain; Sherwyn L. Schwartz; Malcolm Sperling; Walter Wilborn; Hwa-Ming Yang; Sheryl L. Silfen. The Journal of the North American Menopause Society Vol. 4, No. 2, pp. 80 - 88.
“Effects of Co-Therapy with Recombinant Human Insulin-like Growth Factor -I (rhIGF-I) and Insulin on the IGF : IGF Binding Protein (IGFBP) System in IDDM." Kathryn Thrailkill; Teresa Quatrin; Lester Baker; Joyce Kuntze; Alex Bajamonde; Paul Martha, Jr. for the rhIGF - I Study Group; Sherwyn L. Schwartz for the FO695g Study Group; University of Kentucky Children’s Hospital, Lexington, KY 40536; Children’s Hospital of Buffalo, SUNYAB, NY 14222; Children’s Hospital of Philadelphia, PA 19104; Genentech, Inc., South San Francisco, CA 94080.
“Recombinant Human IGF-I Improves Metabolic Control in Adolescents and Young Adults with IDDM." T. Qattrin; K. Thrailkill; L. Baker; J. Kuntze; A. Bajamonde; P Martha, Jr. for the IGF-1 in IDDM Study Group; Sherwyn L. Schwartz for RhIGF-I IDDM Study Group.
“Transurethral Alprostadil For The Treatment Of Erectile Dysfunction In Men With Diabetes: Effect of Duration of Diabetes on Efficacy." Fran E. Kaiser; Marshall B. Block; Stephen Bookin; G. Stephen Decherney; Kenneth S. Hershon; Wolfram E. Nolten; Paul C. Norwood; Sidney Rosenblatt; Julio Rosenstock; Don S. Schalch; Sherwyn L. Schwartz; Darby Stephens; Peter, Y. Tam; Leslie K. Todd; Neil Gesundheit; The Vivus-MUSE Study Group.
“RHIGF-1 Improves Glucose Control in Insulin - Requiring Type 2 Diabetics." Sherwyn L. Schwartz, MD for rhIGF- I Co-Therapy with Insulin (RICI) Study Group.
"The Diabetes Prevention Trial-Type 1 Diabetes ( DPT-1): Enrollment Report." Sherwyn L. Schwartz, MD for the DPT-1 Study Group.
“Efficacy of Troglitazone in Combination with Insulin in NONINSULIN-DEPENDENT DIABETES MELLITUS." Philip Raskin; Jane F. Graveline; Sherwyn L Schwartz, MD.
“Co-Therapy with Recombinant Human Insulin-like Growth Factor- I and Insulin Improves Glycemic Control in IDDM." Kathryn Thrailkill; Teresa Quattrin; Lester Baker; Joyce Kuntze; Alex Bajamonde; Paul Martha for the RHIGF - I in IDDM Study Group; Sherwyn L. Schwartz, M.D. for the RHIGF - 1 in IDDM Study Group.
“Sibutramine Produces Dose- Related Weight Loss." George A. Bray, MD; George L. Blackgurn, MD, PhD; James M. Ferguson, MD; Frank L. Greenway, MD; Adesh K. Jain, MD; Carl M. Mendel, MD; Joseph Mendels, MD; Donna Ryan, MD; Sherwyn L. Schwartz, MD; Monte L. Scheinbaum, PhD, MD; Timothy B. Seaton, M.D.; Adornato, Bruce; Cornblath, David; Kessler, John; Petty, Brent; Chaudhry, Vinay; Schwartz, Sherwyn L.; Rask, Cynthia. Stanford Medical Center, Stanford, CA, USA; John Hopkins, Baltimore, MD., USA; Albert Einstein College of Medicine, Bronx, N.Y.; Diabetes and Glandular Disease Clinic , San Antonio, TX , USA ; Genentech , S. San Francisco, CA, USA.
“Clinical Trial of Recombinant Human Nerve Growth Factor (rhNGF) in Peripheral Neuropathy,” October 1994. Lee, Ian, MD; Doneff, Deborah; Ostrander, John, MD; Schwartz, Sherwyn L., MD; 7th ICO Meeting, Boots Pharmaceuticals, BPI 852 Study.
“ Sibutramine Dose Response and Long-Term Efficacy in Weight Loss, A Double - Blind Study “ and “Sibutramine and Long–Term Weight Loss: % of Patients Losing 5 and 10 % of Baseline Weight." August 1994. Neil Friedman, MD, Lovelace Scientific Resources, Albuquerque, NM; Deborah A. Anzalone, MD; and Anastasia M. Wilson, MA, ZENECA Pharmaceuticals Group, Wilmington, DE, for the Hypertension in Diabetes Study Group.
“Efficacy and Tolerability of Lisinopril and Nifedipine GITS in Associated with Non-Insulin-Dependent Diabetes (NIDDM) ”, supplemental issue of Diabetes, 1994. Davidson, M. H.; Schwartz, S. L.; Fletcher, G. F.; Kwiterovich, P.O.; Superko, H. R.; Smith, L. K.; Marquis, N. R., et. al.
“Efficacy of Combination Cholestyramine and Lovastatin Therapy for the Treatment of Hypercholesterolemia.” Submitted to the American College of Cardiology, 40th Annual Scientific Session, Atlanta, Georgia, March 3 - 7, 1991. Riley, W.; Maclaren, N.; Spillar, R.; Krischer, J.; Silverstein, J.; Malone, J.; Schwartz, S. L.; Macmillan, D.; Rotter, J. Riley, W.; Maclaren, N.; Spillar, R.; Krischer, J; Silverstein, J.; Malone, J.; Schwartz, S. L.; Macmillan, D.; Rotter, J.
“Predictive Value of ICA for IDD.” IDW Immunology and Diabetes Workshops, New York, October 27, 1987. Riley, W. J.; Spillar, R. Malone, J.; Schwartz, S.L.
“The Natural History of Islet Cell Autoantibodies ( ICA) In Relatives of Probands with Insulin Dependent Diabetes Mellitus ( IDD) , ” Diabetes , 1986.
** Sherwyn L. Schwartz; The Diabetes & Glandular Disease Clinic Research Center.
POSTER PRESENTATIONS
A New Topical Medication for the Adjunctive Relief of Painful Diabetic Neuropathy and Postherpetic Neuralgia. Bernstein JE¹, Phillips SB¹, Singer R², Rowe D³, Soufer J, Klapper J, Weintraub J6, Scheffler N, Marcardis A, Corn L9, Schwartz S¹º, Rodiel Laboratories, inc., Vernon Hills, IL; 2 Neurology Clinical Research Inc., Plantation, FL; Palm Beach Research Center, West Palm Beach, FL; Phoenix Internal Medicine, Waterbury CTT; Colorado Neurology and Headache Center, Denver, Co; Michigan Head Pain and Neurological Institute, Ann Arbor, MI; American Center for Foot Health Research, Baltimore MD; Comprehensive Neuroscience, Boynton Beach, FL; Comprehensive Neuroscience, Sarasota, FL; Diabetes & Glandular Disease Clinic, San Antonio, TX. Poster being presented at American Pain Society's Meeting in Vancouver on May 8, 2004. Rodlen Laboratories.
Prevalance of Co-Morbid Metabolic Abnormalities in Non-Diabetic Overweight/Obese Adults. Steven Weinstein,
Catherine Vicary, Sherwyn Schwartz, Marshall Block, Barbara Tardiff. Abstract presented at the AACE Meeting, April
2004.
Response To Testosterone Supplementation With a New Topical Testosterone Gel (Testimä) in Older Men With Diabetes Mellitus. Sherwyn L. Schwartz1*; John P. Rodzvilla2, Allen R. Secrest and Ted M. Smith2. 1Diabetes and Glandular Disease Research Associates, P.A., San Antonio, TX, 78229 and 2Auxilium Pharmaceuticals, Inc., Norristown, PA, 19401. Selected by the Annual Meeting Steering Committee for presentation at ENDO 2003 in Philadelphia, PA., on Saturday, June 21, 2003.
Impact of Achieved Systolic Blood Pressure On Renal Function In Type 2 Diabetic Nephropathy. Marc A. Pohl, MD1; Samuel Blumenthal, MD2; Lawrence G. Hunsicker, MD3 and The Collaborative Study Group4. 1Cleveland Clinic Fdn., Cleveland Ohio; 2Veterans Administration, Milwaukee, Wisconsin; 3University of Iowa Hospitals and Clinics, Iowa City, Iowa and 4Rush Medical College, Chicago, Illinois. Presented at the ASN Meeting, November 2002.
Impact Of Angiotensin Receptor Blockade With Irbesartan On Renal Function At Different Systolic Blood Pressure (SBP) Levels In Type 2 Diabetic Nephropathy. Marc A. Pohl, MD1; Daniel J. Cordonnier, MD2; Samuel Spitalewitz, MD3 and The Collaborative Study Group4. 1Cleveland Clinic Foundation, Cleveland Ohio; 2University of Grenoble, Grenoble, France; 3Brooklyn Hospital Medical Center, Brooklyn, NY and 4Rush Medical College, Chicago, Illinois. Presented at the ASN Meeting, November 2002.
The Severity Of Orthostatic Hypotension Is A Risk Factor In The Progression Of Type 2 Diabetic Nephropathy. Matthew R. Weir, MD and Lawrence G. Hunsicker, MD, for The Collaborative Study Group, Chicago Illinois. Presented at the ASN Meeting, November 2002.
The Presence Of Retinopathy Is Associated With Poor Renal And Cardiovascular Outcomes In Type 2 Diabetic Nephropathy. Roger Rodby, MD1; Richard Gilbert, MD2, for The Collaborative Study Group, 1Chicago, Illinois USA. 2Victoria, Australia. Presented at the ASN Meeting, November 2002.
Predictors Of The Progression Of Renal Insufficiency In Patients With Type 2 Diabetes And Overt Diabetic Nephropathy. John P. Middleton, Julia Lewis, for The Collaborative Study Group University of Texas Southwestern, Dallas, Texas; Vanderbilt University, Nashville, Tennessee. Presented at the ASN Meeting, November 2002.
Cardiovascular Outcomes In The Irbesartan Diabetic Nephropathy Trial (IDNT) Of Patients With Type 2 Diabetes And Overt Nephropathy. Tomas Berl, MD1 for The Collaborative Study Group2. 1Division of Renal Diseases and Hypertension, University of Colorado2, Denver, Colorado Department of Medicine, Rush Medical Center, Chicago, Illinois. Presented at the ASN Meeting, November 2002.
Impact of Use of Insulin, Glargine, on Hbg A1c and BMI in a Specialty (Endocrine) Practice Population.” Jerome S. Fischer, M.D. Riad G. Dirani, M.D., Sherwyn L. Schwartz, M.D., Mark S. Kipnes, M.D., Fernando W. Trigoso, M.D., Amna A. Salhin, M.D., Jacob Vadakekalam, M.D., Daina Dreimane, M.D., Litza Loza, San Antonio, Texas. For presentation at the American Diabetes Association 62nd Scientific Sessions, June 14-18, 2002, San Francisco, California.
EFFICACY AND SAFETY OF INHALED INSULIN (EXUBERA®) COMPARED TO CONVENTIONAL SUBCUTANEOUS INSULIN THERAPY IN PATIENTS WITH TYPE 1 DIABETES: RESULTS OF A 6-MONTH, RANDOMIZED, COMPARATIVE TRIAL. T Quattrin for the Exubera® Phase III Study Group. The Inhaled Insulin Phase III Study Group Investigators: Andrew Ahmann, Jeanie Albu, Stephen Aronoff, Andre Belanger, Judson Black, Nancy Bohannon, Mark Burge, Dennis Carey, M Arthur Charles, William Clarke, Stephen Clement, Michael Davidson, Heather Dean, Ivy Fettes, Pavel Fort, David Gardner, Jeffrey Geohas, Priscilla Hollander, Irene Hramiak, Carol Joyce, Charles Kilo, David Klonoff, Lawrence Leiter, Janet McGill, Adi Mehta, Joseph Milbum Jr, Paul Moore, Teresa Quattrin, Susan Ratzan, Marc Rendell, Sid Rosenblatt, Julio Rosenstock, Stuart Ross, Richard Rowe, Sherwyn Schwartz, Allen Sussman, Robert Tanenberg, Kathryn Thrailkill, W Kenneth Ward, Stuart Weinzimer, Stuart Weiss and Neil White. Poster Presentation at the American Association of Clinical Endocrinologists (AACE), 11th Annual Meeting and Clinical Congress, Hyatt Regency Chicago, Chicago, IL USA. May 1-5, 2002.
“Early Introduction of Oral Insulin in Patients Failing on Diet and Exercise, A Long-term Efficacy Study in Treatment of Type-2 Diabetes.” Sherwyn Schwartz; M.D.; Sherri Shade, R.N., Jayne Eaton, R.N., San Antonio, TX., Pankaj Modi, M.D. , Toronto, CAN. Abstract Selected for Poster Presentation at the American Diabetes Association’s 61st Scientific Sessions. Philadelphia, Pennsylvania. June 22-26, 2001.
“THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWAReÒ): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES.” Bakst A.W., Meletiche D.M., Arnold R., Pettit K., Harjono H., Najib M., Cobitz A., Schwartz S. GlaxoSmithKline, Collegeville PA, Pharmacon International, New York, N.Y. Poster presented at ISPOR meeting May, 2001.
A Clinical Trial In Patients With Overt Type 2 Diabetic Nephropathy. EJ Lewis; LG Hunsicker; WC Clarke for the Collaborative Study Group, Chicago IL and Iowa City, Iowa. Presented at the ASN meeting 2001.
“Pharmacokinetics and Pharmacodynamics of Pulmonary Insulin Delivered via the AERxÒ Insulin Diabetes Management System in Type 1 Diabetics. M. Kipnes, B. Otulana, S. Farr, J. Jendle, J. Thipphawong and S. Schwartz. For presentation at the 36th Annual Meeting of The European Association for the Study of Diabetes, held at the Jerusalem ICC - International Convention Center and the adjacent Crowne Plaza Hotel, September 18, 2000, Jerusalem, Israel.
“Nateglinide, but Not Glyburide, Selectively Enhances Early Insulin Release and More Effectively Controls Post-Meal Glucose Excursions with Less Total Insulin Exposure.” ADA 60th Scientific Sessions, San Antonio TX, Final Program Booklet, June 2000.
“Efficacy and Safety of Apomorphine SI Vs Placebo for Erectile Dysfunction in Diabetic Patients.” ADA 60th Scientific Sessions, San Antonio TX, Final Program Booklet, June 2000
“The Evaluation of Baseline Blood Glucose Levels on Glycemic Control in Pioglitazone-Treated Patients with Type 2 Diabetes.” ADA 60th Scientific Sessions, San Antonio TX, Final Program Booklet, June 2000.
“Effects of Troglitazone on HbA1c and ALT Levels in Clinical Practice”. Sherwyn L. Schwartz, M.D., Jerome S. Fischer, M.D., Mark S. Kipnes, M.D., William F. Trigoso, M.D., San Antonio, TX. For presentation at the President’s Poster Session and Reception, American Diabetes Association 59th Scientific Sessions, San Diego, CA . June 20, 1999.
“Insulin Requirements Decrease After Two Weeks of Subcutaneous Administration of B2036-PEG (Trovertä), A Growth Hormone Antagonist, to Type I Diabetics” Growth Hormone Research Society Annual Meeting, September 1998.